Vanderbilt University Medical Center: 'Off-the-Shelf' CAR T Therapy Shows Promise for Relapsed/refractory Multiple Myeloma
October 05, 2024
October 05, 2024
NASHVILLE, Tennessee, Oct. 5 -- Vanderbilt University Medical Center issued the following news release:
* * *
The therapy, P-BCMA-ALL01, demonstrated a 91% overall response rate for the 23 patients participating in the phase 1 trial.
* * *
Interim results are promising from on ongoing phase 1 clinical trial testing an allogeneic or "off-the-shelf" chimeric antigen receptor Tcell (CAR T) therapy for patients with multiple myeloma who h . . .
* * *
The therapy, P-BCMA-ALL01, demonstrated a 91% overall response rate for the 23 patients participating in the phase 1 trial.
* * *
Interim results are promising from on ongoing phase 1 clinical trial testing an allogeneic or "off-the-shelf" chimeric antigen receptor Tcell (CAR T) therapy for patients with multiple myeloma who h . . .